AGCT's entrepreneurial team
Management and Team
Hans-Joerg Hess, PhD
Hans earned his PhD at the TU Berlin, where he also studied business administration and mechanical engineering. He worked as a consultant for McKinsey & Company and as a senior corporate manager in M&A and business development. Hans was also a partner in an advisory firm specializing in venture capital transactions and co-funded multiple companies.
Dirk Loeffert, PhD
Dirk is a serial entrepreneur, owner of Bluecatalysis, co-founder of Biomillenia and Six Pines NV. He has over 20 years of experience in product development and commercialization in the life science industry. After earning his Ph.D. in immunology, Dirk joined QIAGEN, a global leader in Life Sciences and molecular diagnostics products, where he became Global Head of Product Development Life Sciences and VP Research of Molecular Diagnostics in the US. He has a proven track record in building high-growth profitable product portfolios and has authored numerous patents.
Dr Dimitry Cherkasov
CTO and Founder
Dmitry has conducted in-depth research in nucleic acid chemistry, modified nucleotides and molecular biology at the University of Luebeck. He has authored numerous patents and is also an M.D. As the former head of molecular diagnostics at the University Hospital of Marburg, Dmitry contributes his experience from ten years in clinical diagnostics.
Christian Grunwald, PhD
Christian studied chemistry and was awarded a PhD in biophysical chemistry from the University of Bochum. He worked for several years in different R&D positions at QIAGEN and Miltenyi Biotec. He is an expert in sample-prep and assay technologies and has a strong background in product development.
Darko Gosenca, PhD
Head of Project and Quality Management
Darko received his PhD in biochemistry at the German Cancer Research Center (DKFZ) in Heidelberg. As a postdoc, he gained extensive experience in molecular diagnostics and monitoring of TKI-responsive/resistant patients with myeloid hematological malignancies like chronic myeloid leukemia (CML). In his last position, as interim manager of an IVD manufacturer, he was responsible for business development and quality management.
Fabian Bietz, PhD
Scientist Assay Development
Fabian was awarded a PhD in biochemistry from the University of Giessen. He studied protein/DNA interactions with three generations of "gene scissors". During his PhD and postdoc research, he worked on R&D projects for Cellectis and Syngenta.
Yuan Cao, PhD
Senior Scientist Assay Development
Yuan received a PhD in Medical Genetics from the University of Edinburgh in 2012 and worked for QIAGEN (Suzhou) and Rutgers New Jersey Medical School. Her expertise lies in multiplex PCR-based molecular diagnostic assay development.
Scientist Assay Development
Maren studied biology at the University of Giessen. She worked for four years as a scientist in pancreatic cancer research at the University of Halle/Wittenberg. She has extensive experience in sample preparation and a strong background in basic cancer research.
Office and Laboratory Manager
Claudia studied biochemistry and worked several years as a scientist in basic research on T-cell neoplasia. Due to her studies and work at the University of Greifswald Medical School she gained wide experience in cancer genetics and molecular biology.
Scientist Assay Development
Patrick studied biology at the University of Giessen and gained an M.Sc. Biology degree. Subsequent to his studies, Patrick worked as an R&D Scientist for GFE Blut. He is well trained in developing and validating PCR-based assays and sample preparation technologies.
Scientific Advisory Board
Viktor Adalsteinsson, PhD
Viktor Adalsteinsson is Associate Director of the Gerstner Center for Cancer Diagnostics at the Broad Institute of MIT and Harvard. His research lab focuses on developing novel liquid biopsy techniques for cancer detection, treatment response monitoring, and molecular profiling of cancer evolution. Together with collaborators, he has analyzed over 10,000 liquid biopsy samples to date, and in 2017, Dr. Adalsteinsson was recognized as one of MIT Technology Review’s “Innovators Under 35.” Dr. Adalsteinsson holds a PhD in Chemical Engineering from MIT.
Joachim Ribbe, PhD
Until 2019, Joachim was Vice President Corporate Business Development at QIAGEN, Hilden/Germany. In this function, he was globally responsible for technology and product licensing, for setting up OEM product marketing arrangements, and for strategic alliances in all markets. He joined QIAGEN as a Project Manager Protein Expression in 1992. In this role and in his later function as a Business Unit Manager Protein Expression/Reagents, he was responsible for product development, strategic marketing, and protein-related business development. In 2002, Joachim became Director Corporate Business Development, and in 2004 Executive Director Corporate Business Development. Before joining QIAGEN, Joachim worked for two years at DuPont as a Visiting Scientist in Wilmington/Delaware in the Genetic- and Protein- Engineering Group. Joachim obtained his PhD in microbiology and biochemistry at the University of Hamburg in 1990, working on gene and protein expression in bacteria.
Holger Sültmann, PhD
Holger Sültmann is Head of the Division of Cancer Genome Research at the German Cancer Research Center (DKFZ) within the German Cancer Consortium (DKTK), Heidelberg, Germany, and Full Professor at Heidelberg Medical School. After graduating in biochemistry from Tübingen University/Germany, he did his PhD studies at the Max Planck Institute for Biology in Tübingen and received his state doctorate in Genetics in 2001. His work at DKFZ (since 2000) has included the initiation and coordination of several multi-disciplinary national (DHGP, NGFN) and international (ICGC) cancer genome research projects. The research aim of his division is to deploy high-throughput genomics and epigenomics technologies to identify, characterize, and translate cancer biomarkers for therapy resistance in cancer, especially lung adenocarcinoma. His current focus is on applying liquid-biopsy approaches for early detection and therapy monitoring of cancer.
Norbert is founder, chairman and majority stockholder of Basler AG, a global market leader for digital cameras used in industrial applications (stock symbol: BSL). He is a technology expert in image digitization and a founding investor of AGCT.